Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, Ravulizumab can be used for the researchs of COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome.
Reinheit:
>95.0%
CAS Nummer:
[1803171-55-2]
Target-Kategorie:
Complement System
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
